


PF-07284892

Cat. No.:	HY-153740		
CAS No.:	2498597-94-5		
Molecular Formula:	C ₂₁ H ₂₂ ClN ₇ S		
Molecular Weight:	439.96		
Target:	SHP2		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (227.29 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2729 mL	11.3647 mL	22.7293 mL
		5 mM	0.4546 mL	2.2729 mL	4.5459 mL
10 mM		0.2273 mL	1.1365 mL	2.2729 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic 				

BIOLOGICAL ACTIVITY

Description	PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC ₅₀ value of 21 nM. PF-07284892 decreases the expression of pERK ^{[1][2]} .
IC₅₀ & Target	IC ₅₀ : 21 nM (SHP2) ^[1]
In Vitro	PF-07284892 (100 nM; 4, 18 h) combines with lorlatinib (0-450 nM), binimetinib (0-160 nM) decreases the expression of pERK in H3122 lorR-06, VACO-432 cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PF-07284892 (10 mg/kg; p.o.) shows good oral bioavailability with F% of 85%, 94%, 102%, 64% for mouse, rat, dog, monkey, respectively^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Abdayem P, et al. Ongoing progress in BRAF-mutated non-small cell lung cancer. Clin Adv Hematol Oncol. 2022 Nov;20(11):662-672.

[2]. Drlon A, et al. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov. 2023 Jun 3:OF1-OF13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA